Related by context. All words. (Click for frequent words.) 81 randomized clinical 79 randomized controlled 77 multicenter study 77 randomized controlled trials 75 observational study 74 randomized trials 74 randomized placebo controlled 73 randomized 72 prospective cohort 71 prospective randomized 71 multicenter 71 placebo controlled 71 prospective observational 69 randomized clinical trials 69 randomized controlled clinical 68 meta analysis 67 multicentre 67 double blind placebo 67 randomized double 67 prospective randomized controlled 66 blind randomized 66 retrospective cohort study 66 multicenter randomized 66 longitudinal study 65 nonrandomized 65 placebo controlled clinical 65 substudy 65 randomized controlled clinical trials 65 placebo controlled studies 64 multicentre study 64 double blinded randomized 64 placebo controlled trials 64 clinical trial 64 observational studies 63 randomized multicenter trial 63 RCTs 63 blind randomized placebo 63 longitudinal cohort study 63 subanalysis 63 multicenter prospective 62 randomized blinded 62 blind placebo controlled 62 trials RCTs 62 randomized multicenter 62 multicentre randomized 62 multicenter randomized controlled 62 Randomized controlled 61 prospective multicenter 61 blinded placebo controlled 61 placebo controlled randomized 61 prospective longitudinal 61 multicenter clinical 60 randomized Phase III 60 longitudinal studies 60 multicentre randomized double 60 multicenter randomized double 60 meta analyzes 60 phase IIIb 60 Carotid Revascularization Endarterectomy vs. 60 blinded randomized controlled 60 multicenter randomized clinical 59 subgroup analyzes 59 Phase III randomized 59 retrospective observational study 59 HCV SPRINT 59 Clinical Antipsychotic Trials 58 Intervention Trial 58 multicenter phase 58 TMC# C# 58 prospectively randomized 58 VADT 58 randomized Phase IIb 58 placebo controlled Phase 58 DCCT 58 HPTN 58 Phase IIIb study 58 postmenopausal women 58 study 58 retrospective cohort 58 RE LY ® 57 multicenter trials 57 placebo controlled Phase III 57 blind randomized controlled 57 randomized crossover 57 Phase 2b study 57 prospective nonrandomized 57 blinded randomized 57 observational cohort study 57 RE LY 57 label multicenter 57 ONTARGET 57 prospective randomized placebo 57 Randomized 57 multicenter Phase II 57 prospective randomized multicenter 57 prospective observational cohort 56 dose escalation study 56 phase IIa 56 UKPDS 56 liver transplant recipients 56 double blinded placebo 56 randomized controlled trials RCTs 56 NO# [002] 56 DAPT 56 Phase IIb trial 56 Stenting Trial CREST 56 NICE SUGAR 56 Multicenter 56 multicentre prospective 56 Intervention Trial GAIT 56 ExTRACT TIMI 56 nulliparous women 56 multicenter randomized placebo controlled 56 Phase 1b trial 56 chemoradiotherapy 56 Prostate Lung Colorectal 56 prospective multicentre 56 Phase Ib clinical 56 STEP BD 56 controlled multicenter 56 phase IIb 56 PRoFESS 56 LUX Lung 55 Atherosclerosis MESA 55 Screening Trial 55 placebo controlled clinical trials 55 multicenter placebo controlled 55 ABSORB trial 55 epidemiologic studies 55 metaanalysis 55 cluster randomized controlled 55 phase IIb trial 55 BARI 2D 55 interpersonal psychotherapy 55 Edge STudy 55 Intervention Effectiveness CATIE 55 dose escalation trial 55 Ovarian PLCO Cancer 55 randomly assigned 55 clinical pharmacology studies 55 HORIZONS AMI trial 55 Communities ARIC study 55 Intervention Effectiveness 55 generalizability 55 ADAGIO study 55 Phase 2a clinical 55 pharmacokinetics PK 55 prospective multicenter study 55 calcium supplementation 54 MADIT II 54 Phase IIb 54 Phase 1b clinical 54 BRIM3 54 TAXUS ATLAS 54 STRIDE PD 54 dose dose escalation 54 phase Ib 54 blind multicentre 54 premenopausal women 54 Cochrane Systematic Review 54 neoadjuvant 54 multicenter Phase 54 single ascending dose 54 Meta analyzes 54 REALITY Trial 54 dose escalation clinical 54 randomized blinded placebo 54 CALGB 54 phase IIb clinical 54 nab paclitaxel 54 Framingham Offspring Study 54 Randomized Evaluation 54 Multi Ethnic Study 54 treatment naive genotype 54 HeFT 54 Sorafenib HCC Assessment 54 HF ACTION 54 ConclusionThis 54 Aggressive Drug Evaluation 54 BOLDER II 54 HYVET 54 pegylated interferon alfa 2b 54 noninferiority 54 masked placebo controlled 54 observational cohort 54 OLYMPIA registry 54 psychodynamic psychotherapy 54 bronchial thermoplasty 54 STICH trial 54 SPARCL 53 dose escalation Phase 53 Phase Ia 53 viral kinetic 53 multicenter multinational 53 Phase 2a trial 53 active comparator 53 ACTIVE W 53 Randomised 53 blind placebo 53 Clinical Outcomes Utilizing Revascularization 53 Cholesterol Levels SPARCL 53 Relieve Depression 53 thromboprophylaxis 53 RE LY trial 53 Sequenced Treatment Alternatives 53 clinical trials 53 Randomized Controlled Trial 53 EVEREST II 53 viral kinetics 53 epidemiological studies 53 EURIDIS 53 analgesic efficacy 53 Subgroup analyzes 53 randomized multicenter Phase III 53 HCV RESPOND 2 53 Phase IIIb 53 Prostate Cancer Prevention 53 APTIVUS 53 HOPE TOO 53 riociguat 53 efficacy 53 GISSI 53 Aggressive Reduction 53 ECASS 53 placebo controlled dose escalation 53 AIR2 Trial 53 PRECiSE 53 Digital Mammographic Imaging 53 phase IIa clinical 53 adenoma recurrence 53 iPrEx study 53 ASTEROID 53 chemoradiation 53 prospectively defined 53 Phase 2b clinical 53 Health Initiative WHI 53 HIVNET 53 Observational studies 53 ACCORD 53 recurrent malignant glioma 53 treatment naïve genotype 53 NSABP B 53 Normative Aging Study 53 blinded randomized placebo controlled 53 CHAMPION PCI 53 factorial design 52 randomized Phase 52 APTIVUS r 52 ELCAP 52 CARE HF 52 vitamin D supplementation 52 randomized multicentre 52 dose escalation 52 eptifibatide 52 paclitaxel eluting stents 52 WHIMS 52 ADVANCE PD 52 Multiethnic Study 52 non inferiority 52 ACUITY trial 52 recurrent glioblastoma multiforme 52 Phase 2b trial 52 SYNTAX trial 52 n = 52 CLL8 52 adenotonsillectomy 52 blind multicenter 52 MADIT CRT 52 multicentre randomized controlled 52 SPIRIT III 52 Ovarian Cancer Screening 52 label multicenter Phase 52 tolerability 52 RSD# oral 52 symptomatic BPH 52 statin therapy 52 beta blocker therapy 52 darunavir ritonavir 52 ToGA 52 PRE SURGE 52 post hoc 52 ENESTnd 52 landmark ATHENA 52 oral rivaroxaban 52 SPIRIT IV 52 macrovascular disease 52 CAMMS# 52 Randomized trials 52 rosuvastatin 52 tiotropium 52 CURRENT OASIS 7 52 NCT# ClinicalTrials.gov 52 AVERROES 52 MADIT CRT trial 52 VFEND 52 Clinical trials 52 IMPROVE IT 52 Myocardial Infarction Study 52 Women Ischemia Syndrome 52 randomisation 52 AIR CF1 52 cognitive behavioral therapy 52 desvenlafaxine succinate 52 histologically confirmed 52 antithrombotic therapy 52 PRECISE 52 Phase III clinical 52 BCIRG 52 dosage regimens 52 RG# ITMN 52 liver resection 52 ALLHAT 52 Phase IIb clinical 52 Randomized Clinical Trial 51 warfarin therapy 51 atherogenic dyslipidemia 51 adjuvant chemotherapy 51 TG MV 51 PROactive study 51 TRANSFORMS 51 AIR CF3 51 patients undergoing percutaneous 51 NSTE ACS 51 Multicentre 51 ACOSOG Z# 51 Stenting Trial 51 Phase IIB 51 ritonavir boosted 51 antihypertensive therapy 51 paricalcitol 51 RTOG 51 Phase 1a 51 journal Neurology 51 Thrombolysis 51 phase IIb study 51 deferiprone 51 transcatheter aortic valve implantation 51 lipid lowering therapy 51 longitudinal observational study 51 logistic regression models 51 Efficacy 51 efficacy endpoint 51 Phase III randomized controlled 51 GOUT 51 confirmatory clinical 51 protease inhibitor PI 51 dietary questionnaires 51 polyarticular 51 BOLDER 51 SCD HeFT 51 #:# randomization 51 TAXUS VI 51 ARIXTRA 51 AIM HIGH 51 ENVISION 51 pre menopausal 51 CLARITY study 51 PICSO ® 51 ENDEAVOR IV 51 dose titration 51 adalimumab 51 ticagrelor 51 journal Ophthalmology 51 ENGAGE AF TIMI 51 Phase IIIb clinical 51 Cochrane Database 51 folate supplementation 51 #mg/day [001] 51 AIR CF2 51 carotid artery stenting 51 cohort 51 dabigatran etexilate 51 clopidogrel pretreatment 51 Meta Analysis 51 ASCEND HF 51 LEXIVA r 51 NATRECOR ® 51 Observational Study 51 strontium ranelate 51 Phase 1b 51 Radiation Therapy Oncology 51 pertuzumab 51 IMPROVE HF 51 androgen suppression 51 International Verapamil SR 51 APPRAISE 51 MERLIN TIMI 51 Systematic Treatment 51 hypertensive patients 51 safety tolerability pharmacokinetics 51 symptomatic VTE 51 Wisconsin Sleep Cohort 51 Multicenter AIDS 51 Prospective Randomized Trial 51 dose regimens 51 prospective multicenter randomized 51 CUSTOM II 51 postmenopausal 51 superficial bladder cancer 51 antidepressant therapy 51 PREZISTA r 51 nonpharmacologic 51 efavirenz EFV 51 authors conclude 51 phase 2a 50 PLCO trial 50 ACTEMRA TM 50 carotid artery stenting CAS 50 prospective observational studies 50 Phase #/#a 50 composite endpoint 50 CHAMPION PLATFORM 50 genomewide association study 50 atherosclerotic renal artery stenosis 50 RRMS patients 50 neoadjuvant treatment 50 Randomized Study 50 dietary modification 50 Vertos II 50 glatiramer acetate 50 ATTRACT 50 Antiviral Therapy 50 Phase IIa 50 doxorubicin docetaxel 50 EORTC 50 Acute Coronary Syndromes ACS 50 metastatic RCC 50 Phase IIa trial 50 INTERHEART study 50 venous thromboembolic disease 50 Atherosclerosis Risk 50 label dose escalation 50 Percutaneous Coronary Intervention 50 antiretroviral naïve 50 MADIT 50 multicentric 50 pegylated liposomal doxorubicin 50 CANCIDAS 50 randomized #:# 50 antibiotic prophylaxis 50 HCV infected 50 Lancet Neurology 50 WHI 50 Prospective Randomized 50 PREVENT IV 50 UPLIFT 50 SWOG 50 unblinding 50 Lancet Oncology 50 ABSORB clinical 50 morphometric vertebral fractures 50 Subgroup analysis 50 tipranavir 50 normotensive 50 antioxidant supplementation 50 relapsing multiple sclerosis 50 ATACAND 50 FOSRENOL R 50 dose regimen 50 Phase III VISTA 50 Medicine NEJM 50 number NCT# ClinicalTrials.gov 50 pharmacokinetic studies 50 EchoCRT 50 PERSEUS 50 DPNP 50 ascending dose 50 WHEL 50 CLBP 50 ascending doses 50 radical cystectomy 50 #F FDG PET 50 TAXUS IV 50 MEND CABG 50 CYPHER R Sirolimus eluting 50 Feasibility Trial 50 supplementation 50 dosing cohorts 50 risperidone Risperdal 50 everolimus eluting stents 50 Alpha Tocopherol Beta Carotene 50 Diabetes Interventions 50 iPrEx 50 Complications Trial 50 DSMB 50 Fracture Intervention Trial 50 MOTIVATE 50 duplex ultrasonography 50 noninferior 50 Phase Ib II 50 unstable angina UA 50 GISSI HF 50 antitumor effect 50 BoNTA 50 adjuvant therapy 50 study1 50 AERAS-#/Crucell Ad# 50 FOLPI 50 BRIM2 50 PFO migraine 50 Phase III trials 50 HORIZONS AMI 50 MBCT 50 selenium supplementation 50 Endarterectomy 50 bowel capsule endoscopy 50 bevacizumab Avastin 50 salmeterol fluticasone 50 II Clinical Trial 50 PLCO 50 RoACTEMRA 50 Val MARC 50 IV NSCLC 50 Trandolapril 50 teriflunomide 50 SABCS 50 icatibant 50 BENICAR HCT 50 label multicenter randomized 50 controlled dose escalation 49 logistic regression analysis 49 Systematic Reviews 49 recurrent GBM 49 elective PCI 49 oral anticoagulation 49 ABC/3TC 49 CaPSURE 49 label dose titration 49 pharmacodynamics PD 49 TMC# r 49 candesartan 49 Decompensated Heart Failure 49 CARDIA 49 recurrent prostate cancer 49 GRAVITAS trial 49 boosted protease inhibitor 49 Kaplan Meier analysis 49 thorough QT 49 inhaled corticosteroid therapy 49 NEJM 49 knee OA 49 Val HeFT 49 randomized controlled Phase 49 sorafenib Nexavar 49 unblinded 49 pivotal Phase III 49 bosentan 49 SYNTAX 49 Controlled Trial 49 pharmacokinetic PK 49 aldosterone antagonists 49 afatinib 49 Gynecologic Oncology Group 49 Randomised controlled trial 49 pain palliation 49 CIMZIA TM certolizumab pegol 49 prucalopride 49 solifenacin 49 REYATAZ ritonavir 49 Study AREDS 49 landmark ATHENA trial 49 CYPHER Stent 49 SORT OUT III 49 NCCTG 49 undergoing coronary angiography 49 Phase Ib 49 bendamustine 49 Longitudinal studies 49 virological response 49 ragweed allergic 49 Pharmacotherapy 49 sunitinib malate 49 sirolimus eluting stents 49 cinacalcet 49 premature ejaculation PE 49 metastatic HRPC 49 adjuvant radiotherapy 49 ORMD 49 aldosterone antagonist 49 EmbraceAC 49 XIENCE V Stent System 49 LCP AtorFen 49 Protelos 49 Cohort Study MACS 49 monotherapy 49 Prospective Investigation 49 tolerability pharmacokinetics 49 PHQ 9 49 Rosuvastatin 49 pharmacodynamics 49 CAPRISA 49 ALISTA 49 Multicenter Study 49 postmenopausal osteoporotic women 49 antiretroviral naive 49 ibandronate 49 Elocalcitol 49 prespecified 49 pharmacodynamic profile 49 Rheos System 49 virologic 49 Betaferon ® 49 ACCORD Lipid 49 prostate cancer PCa 49 rFVIIa 49 RIO Lipids 49 hemodialysis patients 49 RESOLUTE clinical 49 basal bolus regimen 49 Communities ARIC Study 49 liver biopsies 49 CORD II 49 histologically proven 49 unfractionated heparin UFH 49 acute mania 49 cilostazol 49 adjuvant tamoxifen 49 quadrivalent HPV vaccine 49 Phase 2b 49 ACCOMPLISH 49 Acute Decompensated Heart Failure 49 RE MODEL 49 pimecrolimus cream 49 dyslipidaemia 49 sentinel node biopsy 49 Phase IIA 49 CATIE 49 secondary efficacy endpoints 49 safety tolerability pharmacokinetic 49 #mg QD [002] 49 VIRAMUNE XR 49 dose escalation phase 49 Evaluation WISE 49 Ranolazine 49 Spine Patient Outcomes 49 safety tolerability 49 Conclusions 49 Glucosamine Chondroitin Arthritis 49 APEX AMI trial 49 Young Adults CARDIA 49 endothelin antagonists 49 Prospective Multicenter 49 oral ibandronate 49 post menopausal 49 peg interferon 49 patients undergoing CABG 49 EMPHASIS HF trial 49 ENDEAVOR 49 stage IIIB 49 journal Lancet Neurology 49 Percutaneous Tibial Nerve Stimulation 49 NCCTG N# 49 radiographic outcomes 49 anti arrhythmic drug 49 Metabolic Efficiency 49 anticoagulation therapy 49 EDEMA3 49 REVIVE Diabetes 49 LITHE 49 phase III ACCLAIM 49 placebo 49 Polyp Prevention Trial 49 claudication 49 psychoeducation 49 Cognitive behavioral therapy 49 Chronic Heart Failure 49 Phase III 49 Acute Ischemic Stroke 49 Systematic Review 49 Clinical Psychiatry 49 buprenorphine naloxone 49 ENDEAVOR clinical 49 zinc supplementation 49 oral deforolimus 49 Phase 1a clinical 49 sirolimus eluting 49 fosbretabulin 49 Screening Trial DMIST 49 BR.# study 49 multicenter Phase III 49 COMFORT II 49 ACTEMRA 49 Phase Ib IIa clinical 49 Cohort 49 antiplatelet therapy 49 relapsed MM 49 macrovascular 49 CombAT 49 antiepileptic drug 49 Phase IIa clinical 49 NHANES III 49 Surgical Treatment 49 refractory CLL 49 axillary lymph node dissection 49 multiple ascending dose 49 bupropion SR 49 HAART regimens 49 correlational 49 Phase III pivotal 49 therapy CBT 49 β blockers 48 Primary endpoints 48 Acute Myocardial Infarction 48 genotypic resistance 48 Raloxifene Evaluation MORE 48 acute ischemic stroke 48 homocysteine lowering 48 Heart Failure Trial 48 mild gestational diabetes 48 glucocorticoid induced osteoporosis 48 telmisartan 48 TDF FTC 48 BEACOPP 48 knee osteoarthritis OA 48 null responder HCV 48 zotarolimus eluting stent 48 prazosin 48 CALGB # [001] 48 vicriviroc 48 meta regression 48 F FDG PET 48 metreleptin 48 euglycemic clamp 48 Left Ventricular Dysfunction 48 Overactive Bladder OAB 48 oral PrEP 48 Endovascular Valve Edge 48 pyridostigmine 48 nonpregnant women 48 COGENT 48 FFNS 48 mixed hyperlipidemia 48 nortriptyline 48 mycophenolate mofetil 48 prophylaxis 48 cystectomy 48 variceal bleeding 48 canakinumab 48 ILLUSTRATE 48 Adjunctive 48 Group RTOG 48 heartwire 48 RAPAFLO R 48 secondary efficacy endpoint 48 venlafaxine XR 48 dexpramipexole 48 ADMIRE HF 48 bolus dose 48 recurrent glioma 48 VITAL Trial 48 SIMPADICO 48 LPV r 48 citalopram 48 pharmacokinetic characteristics 48 Randomised controlled trials 48 knee osteoarthritis 48 factor Xa inhibitor 48 behavioral interventions 48 flibanserin #mg 48 Cochrane reviewers 48 antihypertensive medications 48 NATRECOR R 48 AREDS 48 Degarelix 48 angiographically 48 bevacizumab 48 thrombolytic therapy 48 idraparinux 48 renal transplantation 48 renal tumors 48 pelvic lymphadenectomy 48 pharmacodynamic effects 48 plus ribavirin 48 Tocilizumab 48 lymphadenectomy 48 assessing T DM1 48 CYPHER ® Stent 48 efficacy tolerability 48 quinacrine 48 ZACTIMA 48 periprocedural MI 48 rt PA 48 dyskinesia PD LID 48 Dabigatran 48 pharmacokinetic pharmacodynamic 48 pharmacodynamic PD 48 relapsing MS 48 paroxysmal AF 48 REVLIMID lenalidomide 48 Randomised Study 48 testosterone supplementation 48 LNG IUS 48 DU #b 48 trastuzumab Herceptin ® 48 immunosuppressive regimen 48 postexposure prophylaxis 48 subclinical hypothyroidism 48 fenretinide 48 pharmacokinetic PK study 48 Phase Ib study 48 somatostatin analog 48 postoperative AF 48 Myocardial Infarction 48 #mg dose [003] 48 vitro studies 48 QD dosing 48 ELONVA 48 registrational Phase 48 relapsing remitting MS RRMS 48 urothelial cancer 48 pramlintide metreleptin combination 48 Geriatric Society 48 donepezil 48 abacavir Ziagen 48 Millennium Cohort Study 48 nonoperative 48 ENDEAVOR II 48 prospectively stratified 48 ginkgo biloba extract 48 dual antiplatelet therapy 48 ACCLAIM 48 Eye Disease 48 polysomnogram 48 ABVD 48 noninfectious uveitis 48 Randomized Phase 48 Phase III metastatic melanoma 48 dosing regimens 48 Coronary Artery Bypass Graft 48 Lancet 48 Swedish Mammography Cohort 48 relapsing remitting multiple sclerosis 48 stellate ganglion block 48 lacosamide 48 Dose escalation 48 ALTTO 48 American Geriatrics Society 48 chemoprevention trials 48 ketogenic diet 48 DAPT Study 48 pivotal bioequivalence 48 glucose lowering 48 TOHP 48 Doxil ® 48 multivitamin supplementation 48 peginterferon alfa 2a 48 Placebo controlled 48 ORACLE MS 48 clazosentan 48 DURATION 48 peginterferon alfa 2b 48 cognitive behavioral 48 CAVEATS 48 THIS STUDY 48 Cardiac Allograft Rejection 48 Phase III randomized placebo 48 Phase 2a 48 nephron sparing surgery 48 SPIRIT FIRST 48 Lipid Lowering Treatment 48 clinically meaningful improvements 48 atazanavir ritonavir 48 chemoradiation therapy 48 sunitinib 48 ABCSG 48 goserelin 48 eculizumab therapy 48 secondary endpoint 48 DMIST 48 teriparatide 48 arteriography 48 carotid endarterectomy CEA 48 agomelatine 48 patientswith 48 XIENCE V demonstrated 48 ASCOT LLA 48 nesiritide 48 KRN# 48 velafermin 48 Angiographic 48 trabedersen 48 cardiovascular morbidity 48 transurethral resection 48 cortical stimulation 48 clinically meaningful 48 RECORD1 48 immunohistochemical staining 48 Relieve Depression STAR 48 Xelox 48 statistically significant differences 48 mg/m2 dose 48 Telmisartan 48 MiDAS 48 IMPACT DCM 48 corrected QT interval 48 recurrent venous thromboembolism 48 Phase III placebo controlled 48 stage IIIb IV 48 suppressive therapy 48 MIST II 48 N acetylcysteine 48 CYPHER R stent 48 PIX# [002] 48 CHARISMA trial 48 osteoporotic vertebral compression fractures 48 virologic response 48 SSRI citalopram 48 Study ADCS 48 AA Amyloidosis 48 onset AF 48 Framingham Offspring 48 reboxetine 48 CLARITY TIMI 48 Dialysis Outcomes 48 oral ridaforolimus 47 nondiabetic patients 47 Randomized clinical trials 47 AZILECT R 47 invasive candidiasis 47 oral FTY# 47 intramuscular injections 47 Pharmacokinetic studies 47 rosuvastatin Crestor 47 Abciximab 47 interferon ribavirin 47 eprotirome 47 Combination therapy 47 letrozole 47 Patency 47 Hydroxyurea 47 nonmetastatic prostate cancer 47 Bivalirudin 47 T1DM 47 HIV HCV coinfected 47 CUSTOM III 47 eosinophilic asthma 47 demonstrated clinically meaningful 47 subthreshold depression 47 chromium supplementation 47 pregabalin 47 Denufosol 47 PCI percutaneous coronary 47 ziprasidone 47 underwent liver transplantation 47 TRITON TIMI 47 tibolone 47 multidose 47 colorectal adenoma 47 darunavir r 47 standard chemotherapy regimen 47 PROSTVAC ® 47 abacavir lamivudine 47 HuMax EGFr 47 Enzastaurin 47 optimal dosing 47 COPAXONE R 47 pharmacokinetic interaction 47 inhibitor RG# 47 pharmacological interventions 47 Trial ASCOT 47 psychotherapies 47 mg BID dose 47 dose cohort 47 pharmacologic treatments 47 CRESTOR #mg 47 ERCP 47 AIDS Clinical Trials 47 Sipuleucel T 47 generalisability 47 Alzheimer Disease Neuroimaging Initiative 47 GnRH agonists 47 mg administered orally 47 BR.# 47 ID NCT# 47 Interpersonal psychotherapy 47 thyroidectomy 47 DMARD therapy 47 designated HVTN 47 Intervention Trial Evaluating 47 diabetes mellitus DM 47 PROCRIT therapy 47 Platelet Inhibition 47 PRADAXA 47 Intensive Care Medicine 47 MVA MUC1 IL2 47 topical NSAIDs 47 MAGE A3 ASCI 47 perinatal outcomes 47 stable angina 47 #mg dosing group 47 Torisel 47 infantile colic 47 intracranial hypertension 47 #mg BID [001] 47 Cancer Prevention ATBC 47 undergone radical prostatectomy 47 Netherlands Cohort Study 47 ANCHOR trial 47 liposomal amphotericin B